Please wait while the formulary information is being retrieved.
TRUMENBA (NEISSERIA MENINGITIDIS GROUP B, LIPIDATED FHBP RECOMBINANT)
- Meningococcal vaccination
120 mcg/0.5 mL intramuscular syringe
- Inject 0.5 milliliter (120 mcg) by intramuscular route once
Meningococcal vaccination
- Inject 0.5 milliliter (120 mcg) by intramuscular route once
- None
Contraindicated
- fingolimod
- Gilenya
Severe
Moderate
- None
- None
Contraindicated
- None
Severe
Moderate
- No disease contraindications
TRUMENBA (NEISSERIA MENINGITIDIS GROUP B, LIPIDATED FHBP RECOMBINANT)
- Meningococcal vaccination
- None
- Chills
- Fatigue
- Headache disorder
- Injection site sequelae
- Myalgias
- Pain
More Frequent
Severe
Less Severe
- None
- Arthralgias
- Diarrhea
- Erythema
- Fever
- Nausea
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- None
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Meningococcal Group B Vaccine
No safety and efficacy age < 10 years.
- 1 Day – 10 Years
- No safety and efficacy age < 10 years.
Meningoccocal Grp B Vac, Recom
- Severity Level:
2
- Additional Notes: Insufficient human data avail; consider maternal treatment benefits
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Meningoccocal Group B Vaccine
Insufficient data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Meningococcal vaccination | |
| Z20.811 | Contact with and (suspected) exposure to meningococcus |
| Z23 | Encounter for immunization |
| 0-9 | A-Z |
|---|---|
| Z20.811 | Contact with and (suspected) exposure to meningococcus |
| Z23 | Encounter for immunization |
Formulary Reference Tool